Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Page 1
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: laws p. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-severe psoriasis. Moreover, the long-term benefit of tildrakizumab on physicians' satisfaction and partners' lives of patients with ps …
This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-s …
3D microenvironment attenuates simulated microgravity-mediated changes in T cell transcriptome.
ElGindi M, Sapudom J, Laws P, Garcia-Sabaté A, Daqaq MF, Teo J. ElGindi M, et al. Among authors: laws p. Cell Mol Life Sci. 2022 Sep 5;79(9):508. doi: 10.1007/s00018-022-04531-8. Cell Mol Life Sci. 2022. PMID: 36063234
In particular, there is a lack of understanding of the extent to which microgravity affects the immune system. T cells, key players of the adaptive immune system and long-term immunity, are present not only in blood circulation but also reside within the tissue. ...
In particular, there is a lack of understanding of the extent to which microgravity affects the immune system. T cells, key players of the a …
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group. Yiu ZZN, et al. Among authors: laws p. JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909. JAMA Dermatol. 2022. PMID: 35791876 Free PMC article.
IMPORTANCE: Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient factors that are associated with the survival of each biologic differently (effect modifiers) may inform the decision to choose between biol …
IMPORTANCE: Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient …
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Warren RB, Gold M, Gooderham M, Kircik LH, Lacour JP, Laws P, Liljedahl M, Lynde C, Mørch MH, Sondermann W, Thaçi D. Warren RB, et al. Among authors: laws p. J Drugs Dermatol. 2021 Apr 1;20(4):436-441. doi: 10.36849/JDD.2021.5728. J Drugs Dermatol. 2021. PMID: 33852252 Clinical Trial.
BACKGROUND: Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid relief of symptoms followed by long-term management to maintain remission. This 4-week open-label phase of a long-term proacti …
BACKGROUND: Psoriasis is a chronic disease requiring long-term treatment strategies. Optimal strategies should include initial rapid …
Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists.
Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Raine T, et al. Among authors: laws p. BioDrugs. 2021 Mar;35(2):187-199. doi: 10.1007/s40259-020-00464-5. Epub 2021 Feb 26. BioDrugs. 2021. PMID: 33635522 Free PMC article.
CONCLUSIONS: This consensus highlights the need to strike a balance between clinical freedom and short-term cost restrictions to support equitable resource distribution within the English NHS. ...
CONCLUSIONS: This consensus highlights the need to strike a balance between clinical freedom and short-term cost restrictions to supp …
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.
Laws PM, Downs AM, Parslew R, Dever B, Smith CH, Barker JN, Moriarty B, Murphy R, Kirby B, Burden AD, McBride S, Anstey AV, O'Shea S, Ralph N, Buckley C, Griffiths CE, Warren RB. Laws PM, et al. Br J Dermatol. 2012 Jan;166(1):189-95. doi: 10.1111/j.1365-2133.2011.10638.x. Br J Dermatol. 2012. PMID: 21929536
When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile....
When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-te …
Ustekinumab for the treatment of psoriasis.
Laws PM, Warren RB. Laws PM, et al. Expert Rev Clin Immunol. 2011 Mar;7(2):155-64. doi: 10.1586/eci.11.4. Expert Rev Clin Immunol. 2011. PMID: 21426253 Review.
The most recent Phase III clinical trial has demonstrated the superior efficacy of ustekinumab (regardless of dosing regimen) compared with high-dose etanercept at week 12. Long-term efficacy has been demonstrated over 148 weeks with 64-76% of patients maintaining PASI 75. …
The most recent Phase III clinical trial has demonstrated the superior efficacy of ustekinumab (regardless of dosing regimen) compared with …
Perinatal outcomes of women intending to give birth in birth centers in Australia.
Laws PJ, Tracy SK, Sullivan EA. Laws PJ, et al. Birth. 2010 Mar;37(1):28-36. doi: 10.1111/j.1523-536X.2009.00375.x. Birth. 2010. PMID: 20402719
No statistically significant difference was found in perinatal mortality for term babies of mothers intending to give birth in a birth center compared with term babies of low-risk women intending to give birth in a hospital (1.3 per 1,000 births …
No statistically significant difference was found in perinatal mortality for term babies of mothers intending to give birth in …
Vascular reconstruction in lower limb musculoskeletal tumours.
Spark JI, Charalabidis P, Laws P, Seben R, Clayer M. Spark JI, et al. Among authors: laws p. ANZ J Surg. 2009 Sep;79(9):619-23. doi: 10.1111/j.1445-2197.2009.05016.x. ANZ J Surg. 2009. PMID: 19895517
Review by a multidisciplinary team can produce successful results with low post-operative morbidity and mortality. Longer follow-up is required to determine the long-term implications....
Review by a multidisciplinary team can produce successful results with low post-operative morbidity and mortality. Longer follow-up is requi …
Adverse outcomes of labour in public and private hospitals in Australia: a population-based descriptive study.
Robson SJ, Laws P, Sullivan EA. Robson SJ, et al. Among authors: laws p. Med J Aust. 2009 May 4;190(9):474-7. doi: 10.5694/j.1326-5377.2009.tb02543.x. Med J Aust. 2009. PMID: 19413516
OBJECTIVE: To compare the rate of serious adverse perinatal outcomes of term labour between private and public maternity hospitals in Australia. DESIGN, SETTING AND PARTICIPANTS: A population-based study of 789 240 term singleton births in public and private hospita …
OBJECTIVE: To compare the rate of serious adverse perinatal outcomes of term labour between private and public maternity hospitals in …
12 results